APAC’s antimicrobial resistance-related costs to reach $904b by 2050

Investment in AMR solutions could generate US$10 to 15b in annual healthcare savings.

In Asia Pacific, antimicrobial resistance-related costs are projected to reach up to $904b (US$700b) by 2050, accounting for up to 1% of the region’s gross domestic product according to a report by The Centre for Impact Investing and Practices and the World Economic Forum.

In 2021, AMR caused 4.7 million deaths annually and is estimated to become the leading cause of death by 2050, claiming more than 8 million lives and surpassing cancer.

Beyond health, it threatens global food systems by reducing global livestock production and polluting waterways.

However, the report noted that timely investment in AMR solutions could generate $12.9b (US$10b) to $19.4b (US$15b) in annual healthcare savings and cut annual socio-economic costs by up to US$40b in the region.

($1=US$0.77)

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia